Temsirolimus

Recent Results in Cancer Research

Volumn 184, Issue , 2010, Pages 189-197

  Stock, Christian ^a   Zaccagnini, Massimo ^a   Schulze, Michael ^a   Teber, Dogu ^a   Rassweiler, Jens J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUDARABINE; FLUOROURACIL; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; CELL CYCLE; CHEMICAL STRUCTURE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFECTION; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS;

EID: 77953680249     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-01222-8_13     Document Type: Review

References (34)

1. Linehan WM, Zbar B, Bates SE et al (2001) Cancer of the kidney and ureter. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Williams and Wilkins, Philadelphia, PA, pp 1362-1396
2. Jemal A, Siegel R, Ward E et al (2007) Cancer Statistiscs, 2007. CA Cancer J Clin 57:43-66
3. Larkin JMG, Chowdhury S, Gore ME (2007) Drug insight: advances in renal cell carcinoma and the role of target therapies. Nat Clin Pract Oncol 4(8):470-479
4. Alexandrescu DT, Dasanu CA (2006) Kidney cancer therapy: new perspectivies and avenues. Expert Opin Pharmacother 7(18):2481-2493
5. Motzer RJ, Bukowsky RM (2006) Targeted therapy for metastatic renal carcinoma. J Clin Oncol 24(35):5601-5608
6. Aass N, De Mulder HM, Mickisch GHJ et al (2005) Randomized phase II/III trial of interferon alfa-2a with and without 13- cis -retinoic acid in patients with progressive metastatic renal cell carcinoma: the European organization for research and treatment of cancer genito-urinary tract cancer group (EOTORC 30951). J Clin Oncol 23:4172-4178
7. Rosemberg SA, Lotze MT, Muul ML et al (1985) Observations on the systemic administration of autologus lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313(23):1485-1492
8. Escudier B (2007) Advanced renal cell carcinoma: current and emerging management strategies. Drugs 67(9):1257-1264
9. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 356:2271-2281 (Pubitemid 46849157)
10. Peralba JM, DeGraffenried L, Friedrichs W et al (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892
11. Guertin DA, Sabatini DM (2005) An expanding role for mTOR in cancer. Trends Mol Med 11: 353-361
12. Martin DE, Hall MN (2005) The expandind TOR signaling network. Curr Opin Cell Biol 17: 158-166
13. Thomas GV, Tran C, Mellinghoff IK et al (2006) Hypoxia inducible factors determines sensitivity to ihibitors of mTOR in kidney cancer. Nad Med 12:122-127
14. Sabers CJ, Matrin MM, Brunn JJ et al (1995) Isolation of a protein target of FKBP 12-rapamycin complex in mammalian cells. J Biol Chem 270(2):815-822
15. Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhancedsensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98(18):10314-10319
16. Podsypanina K, Lee RT, Politis C et al (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinaseactivity in Pten+/- mice. Proc Natl Acad Sci US A 98:10320-10323
17. Yu K, Toral-Barza L, Discafani C et al (2001) mTOR, a novel target in breast cancer : the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8(3):249-258
18. HidalgoM BucknerJC, Erlichman C et al (2006) A phase Iand pharmacokinetic study of temsirolimus (CCI-779)administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12:5755-5763
19. Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347
20. Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918
21. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an antivascular endothelia growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
22. Oza AM et al (2005) A phase II study on temsirolimus (CCI-779) in patients with metastaic and/or recurrent endometrial cancer. Proc. 17th Symp Mol. Targets Cancer Thera. Philadelphia, USA, November, 197 AB269
23. Galanis E et al (2005) Phase II trial of tensirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 23:5294-5304 (Pubitemid 46206983)
24. Chang SM et al (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357-361
25. Witzig TE et al (2005a) Phase II trial of single-agent tensirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347-5356
26. Witzig TE et al (2005b) Phase II trial of single-agent tensirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347-5356
27. Ansell SM et al (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma. A phase 2 trial in the north central cancer treatment group. Cancer 113(3):508-514
28. Verhoef G, Hess G et al (2008) Phase III study of patients with relapsed, refractory mantle cel lymphoma treated with temsirolimus compared with investigator's choice therapy. 13th Congress of the European Hematology Association (EHA)
29. Hess G, Verhoef G et al (2008) Phase III study of patients with relapsed , refractory mantle cel lymphoma treated with temsirolimus compared with investigator's choice therapy. 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
30. Motzer RJ, Figlin RA, Hutson TE, et al (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
31. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) AVOREN trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103-2111
32. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428
33. Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, Bukowski RM, Scheuring UJ, Burk K and Escudier B (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 25(Suppl):abstr. 5025
34. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95(9):1148-1154